The Evolution of Risk Classification for Neuroblastoma

Overview

Journal Children (Basel)

Specialty Health Services

Date 2019 Feb 14

PMID 30754710

Citations 59

Authors

Elizabeth Sokol

Ami V Desai

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are risk-stratified using a number of features including age at diagnosis, disease stage, tumor histology, status (amplified versus nonamplified), and tumor cell ploidy. In this paper, we review the evidence for utilizing these features in the risk classification of neuroblastic tumors. Additionally, we review the clinical and biologic criteria used by various cooperative groups to define low, intermediate, and high-risk disease populations in clinical trials, highlighting the differences in risk classification internationally. Finally, we discuss the development of the International Neuroblastoma Risk Group classification system, designed to begin worldwide standardization of neuroblastoma pretreatment risk classification and allow comparison of clinical trials conducted through different cooperative groups.

Citing Articles

Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review.

Bruinsma R, Lekkerkerker C, Fiocco M, Dierselhuis M, Langenberg K, Tytgat G Cancers (Basel). 2025; 17(1.

PMID: 39796644 PMC: 11718975. DOI: 10.3390/cancers17010013.

Tackling ALT-positive neuroblastoma: is it time to redefine risk classification systems? A systematic review with IPD meta-analysis.

Avinent-Perez M, Westermann F, Navarro S, Lopez-Carrasco A, Noguera R Neoplasia. 2024; 60:101106.

PMID: 39733691 PMC: 11743311. DOI: 10.1016/j.neo.2024.101106.

Iwilfin (eflornithine) approved by the FDA as the first and only oral maintenance therapy for high-risk neuroblastoma in adult and pediatric patients: Narrative review.

Shakeel A, Baloch A, Kumari V, Kazmi S, Aftab K, Abid S Medicine (Baltimore). 2024; 103(48):e40662.

PMID: 39612452 PMC: 11608686. DOI: 10.1097/MD.0000000000040662.

Characterisation of Paediatric Neuroblastic Tumours by Quantitative Structural and Diffusion-Weighted MRI.

Tambasco D, Zlotnik M, Joshi S, Moineddin R, Harris S, Villani A J Clin Med. 2024; 13(22).

PMID: 39597804 PMC: 11594407. DOI: 10.3390/jcm13226660.

Late Presentation of a Childhood Neuroblastoma in an Adult Patient.

Al Hashimi I, Siddiqui K, Al Badaai G, Al Jahdhami S Cureus. 2024; 16(10):e72438.

PMID: 39588449 PMC: 11588299. DOI: 10.7759/cureus.72438.

References

Schmidt M, Lal A, Seeger R, Maris J, Shimada H, OLeary M . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005; 23(27):6474-80. DOI: 10.1200/JCO.2005.05.183. View

Look A, Hayes F, Nitschke R, MCWILLIAMS N, Green A . Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984; 311(4):231-5. DOI: 10.1056/NEJM198407263110405. View

Hann H, Evans A, Siegel S, Wong K, Sather H, Dalton A . Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res. 1985; 45(6):2843-8. View

Ikeda H, Iehara T, Tsuchida Y, Kaneko M, Hata J, Naito H . Experience with International Neuroblastoma Staging System and Pathology Classification. Br J Cancer. 2002; 86(7):1110-6. PMC: 2364166. DOI: 10.1038/sj.bjc.6600231. View

Teshiba R, Kawano S, Wang L, He L, Naranjo A, London W . Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014; 17(6):441-9. PMC: 4340697. DOI: 10.2350/14-06-1505-OA.1. View

Campbell K, Gastier-Foster J, Mann M, Naranjo A, Van Ryn C, Bagatell R . Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017; 123(21):4224-4235. PMC: 5650521. DOI: 10.1002/cncr.30873. View

Cao Y, Jin Y, Yu J, Wang J, Yan J, Zhao Q . Research progress of neuroblastoma related gene variations. Oncotarget. 2017; 8(11):18444-18455. PMC: 5392342. DOI: 10.18632/oncotarget.14408. View

Quinn J, Altman A, Frantz C . Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr. 1980; 97(1):89-91. DOI: 10.1016/s0022-3476(80)80139-9. View

Oppedal B, Lie S, Brandtzaeg P . Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer. 1988; 62(4):772-80. DOI: 10.1002/1097-0142(19880815)62:4<772::aid-cncr2820620422>3.0.co;2-u. View

10.

Chicard M, Boyault S, Colmet Daage L, Richer W, Gentien D, Pierron G . Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clin Cancer Res. 2016; 22(22):5564-5573. DOI: 10.1158/1078-0432.CCR-16-0500. View

11.

Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V . Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2010; 47(4):561-71. DOI: 10.1016/j.ejca.2010.10.022. View

12.

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

13.

Twist C, Schmidt M, Naranjo A, London W, Tenney S, Marachelian A . Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019; 37(34):3243-3255. PMC: 6881103. DOI: 10.1200/JCO.19.00919. View

14.

Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-23. PMC: 2993160. DOI: 10.1056/NEJMoa1001527. View

15.

Strother D, London W, Schmidt M, Brodeur G, Shimada H, Thorner P . Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012; 30(15):1842-8. PMC: 3383182. DOI: 10.1200/JCO.2011.37.9990. View

16.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

17.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

18.

Monclair T, Mosseri V, Cecchetto G, De Bernardi B, Michon J, Holmes K . Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma. A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group. Pediatr Blood Cancer. 2015; 62(9):1536-42. DOI: 10.1002/pbc.25460. View

19.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

20.

De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R . Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008; 99(7):1027-33. PMC: 2567095. DOI: 10.1038/sj.bjc.6604640. View